603 results about "Tuberculosis mycobacterium" patented technology

The invention relates to a high-specificity diagnostic reagent and kit for mycobacterium tuberculosis infection, and relates to the technical field of tuberculosis diagnostic products. The fusion protein contains a first fusion protein and a second fusion protein; the first fusion protein is a protein ESAT-6-CFP-10 encoded by a mycobacterium tuberculosis genome RD1 region, and the second fusion protein is a protein CFP-21-MPT-64 encoded by a mycobacterium tuberculosis genome RD2 region. According to the invention, tuberculosis specific RD2 region antigens CFP21 and MPT64 and RD1 region antigens ESAT-6 and CFP-10 are combined to be applied to diagnosis of mycobacterium tuberculosis infection for the first time, by virtue of the difference degree of RD1 and RD2 in mycobacterium antigen cross reactivity, immunogenicity advantages of the two antigens are concentrated, epitopes of the antigens are increased, human MHC limitation and polymorphism are overcome, and advantage complementation is achieved.

The invention provides an intracellular mycobacterium tuberculosis in-situ nucleic acid detection method based on CRISPR / Cas and application, and the method comprises the following steps: S1, designing crRNA and a primer pair of a mycobacterium tuberculosis target gene sequence, and synthesizing a single-stranded DNA fluorescent probe; s2, preparing a standard solution containing a target gene sequence, and incubating with a CRISPR / Cas12a system; s3, extracting nucleic acids of different types of bacteria, uniformly mixing the nucleic acids of different types of bacteria with the CRISPR / Cas12a system, and incubating; s4, incubating an attenuated strain of mycobacterium tuberculosis and the DNA fluorescent probe, infecting macrophages, and incubating to obtain infected cells; s5, electrically transferring a CRISPR / Cas12a system into the infected cells in S4 by utilizing an electroporation technology, incubating, and detecting the intensity of a fluorescence signal; and S6, performing quantitative and positioning analysis on the detected fluorescence signal to complete detection, and directly introducing a CRISPR / Cas12a system into the macrophage by adopting an electroporation technology to realize intracellular in-situ detection, thereby avoiding the operation complexity of a nucleic acid extraction link and the loss of detection sensitivity in the prior art.

The invention discloses an application of cryptotanshinone in preparation of an anti-mycobacterium tuberculosis drug, and relates to the technical field of bioengineering. The molecular formula of the valerianin disclosed by the invention is C19H20O3. The mycobacterium tuberculosis is a mycobacterium tuberculosis H37Rv strain. Cryptotanshinone is disclosed as a natural-source compound for the first time, has the dual advantages of high efficiency and low toxicity, has an obvious effect of resisting mycobacterium tuberculosis, provides a brand new candidate drug scheme with development potential for solving the difficulty of tuberculosis treatment, and has great scientific value and application prospect.

The invention discloses a method for rapidly detecting mycobacteria. The method comprises the following steps: using a primer pair for detecting the Mycobacterium tuberculosis, wherein the primer pair comprises an upstream primer and a downstream primer; the upstream primer comprises a nucleotide sequence as shown in SEQ ID NO: 1 or 2, and the downstream primer comprises a nucleotide sequence as shown in any one of SEQ ID NO: 3-6. According to the present invention, the RNA of the MTB viable bacteria in the biological sample can be rapidly and accurately detected with high sensitivity, the detection limit is reduced by 1000 times compared with the existing NASBA kit, the template requirement is reduced, and the better choice is provided for the instant detection of MTB.

The invention discloses a primer composition and application thereof. According to the invention, a group of primer compositions is obtained aiming at mycobacterium tuberculosis complex group identification and drug resistance related genes thereof. The primer composition can be combined with nucleic acid matrix-assisted laser desorption ionization time-of-flight mass spectrometry to detect a mycobacterium tuberculosis complex group, and can also detect the mutation conditions of 18 drug-resistant genes and 92 gene mutations related to drug resistance of 21 common first-line and second-line antituberculous drugs / types in the mycobacterium tuberculosis complex group. The medication is guided. Based on a MassARRAY technical platform, the primer composition has the advantages of good accuracy, high sensitivity, short required time and high efficiency when being used for detecting the mycobacterium tuberculosis complex group and the drug resistance thereof, is suitable for various sample types, can meet clinical detection requirements, is beneficial to clinical diagnosis and medication guidance of mycobacterium tuberculosis, and realizes precise treatment of pulmonary tuberculosis.

The invention provides a preparation method and application of nano protein, and the preparation method comprises the following steps: adopting lactoferrin as a carrier, reducing by using a reducing agent, stirring with DNA enzyme and a DNA chimeric agent, and obtaining the nano protein by using a nano precipitation method, the preparation method comprises the following steps: by taking lactoferrin as a nano-carrier, opening a folding structure of the lactoferrin by utilizing glutathione, then adding chloroquine and DNA enzyme, and finally, accelerating the reformation of a disulfide bond of the lactoferrin by stirring. On one hand, a DNA chimeric agent chloroquine is utilized to maintain the eDNA configuration in the biological membrane to be B type, and on the other hand, the mycobacterium tuberculosis biological membrane is efficiently disintegrated based on the enzymatic hydrolysis capability of DNA enzyme; the nano protein can efficiently grab iron ions at a focus part based on the iron chelation characteristic of the nano protein, so that bacteria die due to iron deficiency, and the bioavailability of DNA enzyme and the hydrolysis efficiency of a biological membrane can be improved to a great extent.

The present invention relates to a recombinant Mycobacterium bovis BCG strain comprising a plasmid having a short guide RNA (sgRNA) target sequence for knocking out the Mb3739 gene. Also provided are vaccine compositions for eliciting an immune response against Mycobacterium tuberculosis comprising a recombinant Mycobacterium bovis BCG strain engineered to activate the NOD-1 pathway. The recombinant Mycobacterium bovis BCG strain or vaccine composition can be used in a method against an immune response initiated by Mycobacterium tuberculosis. The invention also relates to a method for obtaining the recombinant bovine mycobacterium BCG strain.

The invention discloses a mycobacterium tuberculosis tandem DNA vaccine W543 as well as a preparation method and application thereof. The DNA vaccine W543 provided by the invention is a novel mycobacterium tuberculosis DNA vaccine with multiple antigen immunodominance epitopes, which is constructed by connecting polypeptides or epitope coding genes of a mycobacterium tuberculosis proliferation period antigen and a latent related antigen in series through a linker by virtue of genetic engineering and inserting the polypeptides or epitope coding genes into an eukaryotic expression vector pVAX1. Experiments prove that the mycobacterium tuberculosis specific tandem DNA vaccine W543 disclosed by the invention is used as an immunomodulatory preparation, mainly stimulates immune response of Th1 type, and can significantly enhance the specific cellular immune function of mice; as a preventive treatment preparation, the bacterial count of lung and liver tissues can be reduced, the lesion range of the lung tissues is remarkably reduced, the lesion is relieved, and the treatment effect is slightly superior to that of an existing commercial tuberculosis latent infection prevention and treatment preparation, namely, microkalidium vaccine.

Provided herein are nucleic acid vaccine constructs comprising synthetic polynucleotides encoding a Mycobacterium tuberculosis (Mtb) RelA-SpoT homolog (RSH) protein, RelMtb, or a functional portion, fragment, or variant thereof, conjugated to a macrophage inflammatory protein-3 alpha (MIP-3α) or other chemokine that binds to a chemokine receptor 6 (CCR6), or a functional portion, fragment, or variant thereof, or to an antibody, or antigen binding portion thereof, that binds to a CCR6. Methods for making the vaccine constructs and their use in prophylaxis and treatment of Mtb infections are also provided.

The invention discloses a detection kit and method for Mycobacterium tuberculosis complex and rifampicin drug-resistant mutation, and belongs to the technical field of biologication.A Taqman probe and a molecular beacon are combined, a fluorescent signal is generated based on a Taq enzyme hydrolysis fluorescent probe, the fluorescent signal is accumulated, and the molecular beacon is used for detecting the drug-resistant mutation of the Mycobacterium tuberculosis complex and the rifampicin drug-resistant mutation of the Mycobacterium tuberculosis complex and the rifampicin drug-resistant mutation. According to two technical principles that a molecular beacon and a fluorescent product are hybridized to generate a fluorescent signal, fluorescent PCR amplification is adopted for detection of one target spot in a monochromatic fluorescent channel, and a melting curve mode of a probe and a target gene is adopted for detection of the other target spot. Therefore, two target spots can be detected and analyzed in a monochromatic fluorescence channel at the same time. Single-tube multiple detection is achieved, and mycobacterium tuberculosis complex group detection and mycobacterium tuberculosis rifampicin drug-resistant mutation site detection can be achieved at the same time.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The invention discloses identification and application of a mycobacterium tuberculosis bacteriophage susceptibility gene, and a gene target which affects mycobacterium bacteriophage infection efficiency is obtained through combined application of a mycobacterium tuberculosis CRISPR-KO library and a CRISPRi library and bacteriophage D29 infection screening. Reagents or drugs targeting phage susceptibility genes or encoded proteins thereof are screened based on the gene targets, and the reagents or drugs can knock out the phage susceptibility genes or inhibit expression of the phage susceptibility genes, or inhibit activity of the encoded proteins of the phage susceptibility genes, serve as phage synergists, or are combined with antibiotics to be used with phages, and can be used for preparing drugs for treating the phage susceptibility genes or the encoded proteins of the phage susceptibility genes. The bacteriophage-antibiotic composition has the advantages that a synergistic sterilization effect is achieved, a new strategy is provided for bacteriophage-antibiotic combined treatment of drug-resistant mycobacterium infection, rapid sterilization is expected to be achieved, the treatment course is shortened, and finally the target of rapid treatment of tuberculosis and other pathogenic mycobacterium infection is achieved.

The invention provides a composition and a kit for detecting mycobacterium tuberculosis and drug resistance thereof. Specifically, the invention provides a composition of primers and probes for detecting mycobacterium tuberculosis and drug resistance thereof, and genes targeted by the primers and the probes comprise an IS6110 insertion sequence, an IS1081 insertion sequence, a 16s rRNA sequence, an rpoB gene, a katG gene, an inhA gene, an ahpC gene, a gyrA gene and a gyrB gene.

The present invention provides a microfluidic detection chip for tuberculosis-specific cellular immunity, belonging to the technical field of Mycobacterium tuberculosis detection. The chip is primarily composed of a three-layer structure, assembled sequentially from bottom to top: a chip bottom sealing plate, a chip substrate, and a chip top sealing plate. The chip is equipped with detection units for multiple samples, capable of simultaneously performing IGRA detection of negative controls, positive controls, and a sample control of 1-8 test samples. Furthermore, the present invention provides an assembly process for a centrifugal microfluidic detection chip for tuberculosis-specific cellular immunity, as well as a detection method and application of chip-based IGRA using the chip. The chip-based IGRA demonstrated a 100% overall concordance rate between test results and those of conventional IGRA. Furthermore, the chip-based IGRA enables detection of very small numbers of test samples, while improving the throughput and speed of IGRA detection, thus showing significant application prospects for IGRA detection of large numbers of clinical samples.

The invention provides a compound as shown in a formula (I), a stereoisomer thereof, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a crystal form thereof, an isotope derivative thereof, a prodrug thereof and a metabolite thereof. The solvate or hydrate of the compound can be used for preparing a pharmaceutical composition for treating and / or preventing diseases related to mycobacterium tuberculosis and / or nontuberculous mycobacterium. The compound provided by the invention has an excellent bactericidal effect and strong specificity, has no cross resistance with the existing antituberculosis drugs, and provides a breakthrough direction for treatment of drug-resistant tuberculosis.

The invention discloses a combination of blocking agents for detecting drug resistance of mycobacterium tuberculosis. The combination comprises a first peptide nucleic acid blocking agent, a second peptide nucleic acid blocking agent, a third peptide nucleic acid blocking agent and a fourth peptide nucleic acid blocking agent. The first peptide nucleic acid blocker covers codons 511 and 513 of the rpoB gene. The second peptide nucleic acid blocker covers the codon 516 of the rpoB gene. And the third peptide nucleic acid blocking agent covers the codon 526 of the rpoB gene. And the fourth peptide nucleic acid blocking agent covers codons 531 and 533 of the rpoB gene. The respective sequences of the first peptide nucleic acid blocker, the second peptide nucleic acid blocker, the third peptide nucleic acid blocker, and the fourth peptide nucleic acid blocker match the wild type of the corresponding sequence of the rpoB gene. The invention also provides a kit and a method for detecting the drug resistance of mycobacterium tuberculosis.

The invention discloses application of Rv2610 in preparation of a medicine for resisting mycobacterium tuberculosis infection, and belongs to the technical field of biology. The invention finds that the Rv2610 can promote the adhesion capacity of mycobacterium tuberculosis to macrophages and inhibit the expression of early inflammatory molecules TNF-alpha and IL-1beta of the macrophages, and in a mouse infection model, the Rv2610 promotes the colonization of mycobacterium in the lung in vivo. The Rv2610 can be used as a new drug target for resisting tuberculosis infection, and an inhibitor of the Rv2610 can be used for preparing a drug for resisting mycobacterium tuberculosis infection. The invention provides new tools and ideas for clinical prevention and treatment of tuberculosis, particularly has wide prospects in the aspects of development, clinical application and the like of antituberculosis drugs and vaccines, and can also be applied to the field of scientific research or guide development of inhibitors for inhibiting mycobacterium tuberculosis from infecting host macrophages. The invention has important application value for obtaining new anti-tuberculosis drug targets and screening new drugs.

The invention belongs to the technical field of medicines, and discloses a mycobacterium tuberculosis fusion protein LT57 construction and expression purification method, a mycobacterium tuberculosis cell wall antigen Rv0518 and mycobacterium tuberculosis PE / PPE family antigens PE25 and PPE41 are fused, and the fusion protein PE25-linker-PPE41-Rv0518 is constructed by connecting the fusion protein Rv0518 and the fusion protein PPE41 through flexible peptide fragments. The fusion protein is expressed in a prokaryotic expression vector E.coli BL21 (DE3), and is obtained through column chromatography purification. The fusion protein LT57 and an adjuvant DP are combined to construct a tuberculosis subunit vaccine, a relatively strong specific cellular immune response aiming at a specific antigen of mycobacterium tuberculosis can be induced in a mouse body, the long-term generation of memory T cells is promoted, and the tuberculosis subunit vaccine has relatively strong immunogenicity. The novel fusion protein LT57 is successfully constructed, expressed and purified, and antigen-specific cellular immunity and humoral immunity can be induced.

The invention relates to the technical field of biological medicines, in particular to a tuberculosis vaccine antigen and a vaccine. In particular to application of a mycobacterium tuberculosis Rv1787 gene in preparation of a vaccine for preventing and / or treating tuberculosis, in the application, the sequence of the Rv1787 gene or an encoding product thereof is defined, and the Rv1787 gene and the encoding product thereof serve as antigens, have mycobacterium tuberculosis specificity, and can be used for preparing a vaccine for preventing and / or treating tuberculosis. According to the mycobacterium tuberculosis vaccine, identification and response of an organism immune system to mycobacterium tuberculosis can be accurately stimulated, non-specific immune response to other normal tissues is avoided, a brand new and specific molecular target spot is provided for preventing and treating tuberculosis, and the limitation that a traditional vaccine depends on a single antigen or an attenuated strain is broken through. A specific expression product of the gene can stimulate directional recognition and attack of an organism immune system on mycobacterium tuberculosis, the pertinence and effectiveness of vaccines are remarkably improved, and a new path is provided for solving the problem of tuberculosis prevention and treatment.

The invention relates to a mycobacterium tuberculosis vaccine, in particular, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a granular protein component. The granular protein component comprises nano-granular protein, and the antigen component and the granular protein component are covalently bound through a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. The cell immunogenicity and the antibody immunogenicity of the vaccine are excellent. The invention also discloses a preparation method of the mycobacterium tuberculosis vaccine.

The invention is applicable to the field of gene engineering, and provides a double-antibody sandwich ELISA (enzyme-linked immuno sorbent assay) detection kit for mycobacterium tuberculosis PPE18 protein and application thereof, the detection kit comprises a PPE18 mouse monoclonal antibody 1H14 and an HRP (horse radish peroxidase) labeled PPE18 mouse monoclonal antibody 3L24; the amino acid sequence of the PPE18 protein is as shown in SEQ ID NO. 1 in a sequence table; the heavy chain sequence of the PPE18 mouse monoclonal antibody 1H14 is as shown in a sequence table SEQ ID NO.2, and the light chain sequence of the PPE18 mouse monoclonal antibody 1H14 is as shown in a sequence table SEQ ID NO.3; a heavy chain sequence of the PPE18 mouse monoclonal antibody 3L24 is shown as a sequence table SEQ ID NO.4, and a light chain sequence of the PPE18 mouse monoclonal antibody 3L24 is shown as a sequence table SEQ ID NO.5. According to the invention, the PPE18 mouse monoclonal antibody 1H14 is used as a capture antibody, and the PPE18 mouse monoclonal antibody 3L24 is used as a detection antibody, so that a double-antibody sandwich ELISA detection system can be established, and the kit has good sensitivity, specificity and repeatability, can effectively detect M.tb, and provides a rapid detection method and a monitoring means for prevention and control of tuberculosis.

The invention relates to an application of bisphenicol in preparation of a product for inhibiting mycobacterium tuberculosis, the bisphenicol has a very good antibacterial effect on mycobacterium tuberculosis, the MIC of the bisphenicol on a mycobacterium tuberculosis standard strain (ATCC25618) is 0.125 mu g / mL, and the MBC of the bisphenicol on the mycobacterium tuberculosis standard strain is 0.25 mu g / mL. The bisphenicol has low cytotoxicity and good safety, and can be used as a candidate drug to be applied to the development of anti-mycobacterium tuberculosis infection drugs.

The invention belongs to the technical field of biology, and particularly relates to a primer probe combination and a kit for identifying a mycobacterium tuberculosis and mycobacterium avium complex. The composition for detecting mycobacterium tuberculosis comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO: 1 or SEQ NO: 2; the nucleotide sequence of the downstream primer is as shown in SEQ NO: 3 or SEQ NO: 4 or SEQ NO: 5; a probe having a nucleotide sequence as shown in SEQ NO: 6; the composition for detecting the Mycobacterium avium complex comprises an upstream primer and a downstream primer, wherein the nucleotide sequence of the upstream primer is shown as SEQ NO: 7 or SEQ NO: 8 or SEQ NO: 9; the nucleotide sequence of the downstream primer is as shown in SEQ NO: 10 or SEQ NO: 11 or SEQ NO: 12; the nucleotide sequence of the probe is as shown in SEQ NO: 13. A new primer probe combination is screened out and used for differential diagnosis of Mtb and MAC, the primer probe combination has good specificity, the result is analyzed by a real-time fluorescent quantitative PCR instrument, the result is visual and continuous, operation is easy and rapid, and the false positive rate is low.

The present invention provides an electrochemical aptamer sensor for detecting Mycobacterium tuberculosis ESAT‑6 antigen. The sandwich electrochemical biosensor uses a new type of MXene@Hemin‑AuNPs nanozyme as a signal amplifier and N‑CNTs‑AuNPs as a sensing interface to detect the Mycobacterium tuberculosis-specific antigen ESAT‑6 in the serum of tuberculosis patients, providing a new method for the diagnosis of tuberculosis.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

Provided here are nucleic acid constructs containing a Mycobacterium tuberculosis genome comprising a mutation (such as a deletion) of the sigH gene (AsigH) and a mutation (such as a deletion) of at least one additional gene, and mutant Mycobacterium tuberculosis encoded by the nucleic acid constructs. Also provided are methods of making such nucleic acid constructs and Mycobacterium tuberculosis mutants, and uses thereof. The construct can stimulate an immune response against Mycobacterium tuberculosis in a subject, and can be used as live attenuated vaccines.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

The invention discloses a CRISPR-Cas13a (clustered regularly interspaced short palindromic repeats-CRISPR-Cas13a) double crRNA (ribonucleic acid) system which is established by using ERASE test paper and is used for detecting the rifampicin resistance of mycobacterium tuberculosis on site. The CRISPR-Cas13a double crRNA-system comprises a Cas13a protein and crRNA, or a complex formed by the Cas13a protein and the crRNA; the crRNA comprises an anchoring sequence and a guide sequence; the anchoring sequence is used for being combined with Cas13a protein; the guide sequence is used for targeting mutation target sequences of sites 531, 526, 516 and 513 in a mycobacterium tuberculosis drug-resistant gene rpoB gene; the target sequence of the mycobacterium tuberculosis is located at the 2317th site to the 2597th site of the rifampicin drug-resistant gene rpoB. On the basis of a CRSPR-Cas13a nucleic acid detection technology, result interpretation is performed through RAA amplification in combination with a line elimination method (ERASE) lateral flow chromatography test paper, and experiments prove that the kit can target high-frequency mutation sites of four rifampicin drug-resistant genotypes at the same time, has good detection sensitivity and specificity, and can be used for detecting the rifampicin drug-resistant genotypes of the rifampicin drug-resistant genotypes of the rifampicin drug-resistant genotypes of the rifampicin drug-resistant genotypes. The method can realize rapid, efficient, simple and convenient detection of mycobacterium tuberculosis rifampicin drug-resistant nucleic acid, has a sensitivity of 10 copies / [mu] L, and has an important application value.

The invention discloses a primer composition for detecting drug resistance of mycobacterium tuberculosis, a related product and application, and belongs to the field of pathogen detection. The primer composition comprises a primer pair aiming at an rpoB gene, a primer pair aiming at a katG gene, a primer pair aiming at an inhA gene, a primer pair aiming at an ahpC gene, a primer pair aiming at a gyrA gene and a primer pair aiming at a gyrB gene. According to the invention, mutation of mycobacterium tuberculosis complex and rifampicin, isoniazide and quinolone drug resistance related genes rpoB, katG, inhA, ahpC, gyrA and gyrB genes in sputum of a tuberculosis patient can be detected at one time, single-tube multiple high-sensitivity detection is realized, wild genes and mutant genes are accurately distinguished, and serious cross reaction is avoided.

The present invention relates to novel rufamycin analogs that target the ClpC1 protease. The compounds of the present invention have antibacterial activity, e.g., with anti-tuberculosis properties, and are useful in the treatment of e.g. Tuberculosis.